Biofortuna have recently completed the design and development of a set of 384 multiplex genotyping Taqman-based PCR reactions.
Biofortuna performed the following:
The designed reactions delivered by Biofortuna have been launched by the client as their flagship product. The product family is currently undergoing CE marking.